Novel treatments in B cell non-Hodgkin’s lymphomas
Cet article passe en revue les nouveaux traitements récemment autorisés par la "US Food and Drug Administration" pour les lymphomes non hodgkiniens à grandes cellules B
The improved understanding of lymphoma biology and recent advances in the field of cancer immunology have paved the way for the development of many effective small molecule inhibitors and immunotherapies in B cell non-Hodgkin’s lymphomas. This article reviews novel treatments that have been approved recently by the US Food and Drug Administration and are now routinely used in clinical practice. It discusses their mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in the treatment paradigm of different types of B cell non-Hodgkin’s lymphoma. It also reviews other exciting novel treatments that are not yet approved but have unique mechanisms of action and have shown encouraging early results.
BMJ , article en libre accès, 2021